183 related articles for article (PubMed ID: 29782974)
41. Nanoparticle-mediated delivery of siRNA for effective lung cancer therapy.
Kim YD; Park TE; Singh B; Maharjan S; Choi YJ; Choung PH; Arote RB; Cho CS
Nanomedicine (Lond); 2015; 10(7):1165-88. PubMed ID: 25929572
[TBL] [Abstract][Full Text] [Related]
42. Specific HIV-1 env gene silencing by small interfering RNAs in human peripheral blood mononuclear cells.
Park WS; Hayafune M; Miyano-Kurosaki N; Takaku H
Gene Ther; 2003 Nov; 10(24):2046-50. PubMed ID: 14566364
[TBL] [Abstract][Full Text] [Related]
43. Is the Efficiency of RNA Silencing Evolutionarily Regulated?
Ui-Tei K
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187367
[TBL] [Abstract][Full Text] [Related]
44. siRNA delivery systems for cancer treatment.
Oh YK; Park TG
Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
[TBL] [Abstract][Full Text] [Related]
45. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
46. Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions.
Schubert S; Grünweller A; Erdmann VA; Kurreck J
J Mol Biol; 2005 May; 348(4):883-93. PubMed ID: 15843020
[TBL] [Abstract][Full Text] [Related]
47. Multifunctional nanocarrier based on clay nanotubes for efficient intracellular siRNA delivery and gene silencing.
Wu H; Shi Y; Huang C; Zhang Y; Wu J; Shen H; Jia N
J Biomater Appl; 2014 Apr; 28(8):1180-9. PubMed ID: 23985535
[TBL] [Abstract][Full Text] [Related]
48. Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
Takahashi Y; Nishikawa M; Takakura Y
Adv Drug Deliv Rev; 2009 Jul; 61(9):760-6. PubMed ID: 19386274
[TBL] [Abstract][Full Text] [Related]
49. Dual-target gene silencing by using long, synthetic siRNA duplexes without triggering antiviral responses.
Chang CI; Kang HS; Ban C; Kim S; Lee DK
Mol Cells; 2009 Jun; 27(6):689-95. PubMed ID: 19533030
[TBL] [Abstract][Full Text] [Related]
50. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook.
Shukla S; Sumaria CS; Pradeepkumar PI
ChemMedChem; 2010 Mar; 5(3):328-49. PubMed ID: 20043313
[TBL] [Abstract][Full Text] [Related]
51. Efficient construction of an inverted minimal H1 promoter driven siRNA expression cassette: facilitation of promoter and siRNA sequence exchange.
Nassanian H; Sanchez AM; Lo A; Bradley KA; Lee B
PLoS One; 2007 Aug; 2(8):e767. PubMed ID: 17712415
[TBL] [Abstract][Full Text] [Related]
52. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
[TBL] [Abstract][Full Text] [Related]
53. Gene silencing in Echinococcus multilocularis protoscoleces using RNA interference.
Mizukami C; Spiliotis M; Gottstein B; Yagi K; Katakura K; Oku Y
Parasitol Int; 2010 Dec; 59(4):647-52. PubMed ID: 20817121
[TBL] [Abstract][Full Text] [Related]
54. RNA interference: new mechanisms for targeted treatment?
Woessmann W; Damm-Welk C; Fuchs U; Borkhardt A
Rev Clin Exp Hematol; 2003 Sep; 7(3):270-91. PubMed ID: 15024970
[TBL] [Abstract][Full Text] [Related]
55. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
Ku SH; Kim K; Choi K; Kim SH; Kwon IC
Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
[TBL] [Abstract][Full Text] [Related]
56. Genomewide view of gene silencing by small interfering RNAs.
Chi JT; Chang HY; Wang NN; Chang DS; Dunphy N; Brown PO
Proc Natl Acad Sci U S A; 2003 May; 100(11):6343-6. PubMed ID: 12730368
[TBL] [Abstract][Full Text] [Related]
57. Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes.
Hossain S; Stanislaus A; Chua MJ; Tada S; Tagawa Y; Chowdhury EH; Akaike T
J Control Release; 2010 Oct; 147(1):101-8. PubMed ID: 20620182
[TBL] [Abstract][Full Text] [Related]
58. Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles.
Geng CM; Ding HL
Chin Med J (Engl); 2011 Jan; 124(1):106-10. PubMed ID: 21362317
[TBL] [Abstract][Full Text] [Related]
59. Nanoparticle-mediated delivery of small RNA molecules in tumor therapy.
Aigner A; Fischer D
Pharmazie; 2016 Jan; 71(1):27-34. PubMed ID: 26867350
[TBL] [Abstract][Full Text] [Related]
60. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
